Interestingly, one strategy to enhance the potency of therapeutic antibodies for (tumor) cytotoxicity involves the introduction of IgG3 features into an IgG1 backbone or the use of complete IgG3 allotypic variants with extended half-life (61). This evidence concerns the gene IGHG3 and neoplasm.